Recombinant IFN-γ1b Treatment in a Patient with Inherited IFN-γ Deficiency
Journal of Clinical Immunology · 2024
DOI: 10.1007/s10875-024-01661-5 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Clinical Immunology, 2024. Verfasst von Jérémie Rosain und 19 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Necker Hospital for Sick Children, INSERM U1163, Paris, France. jeremie.rosain@in…. Hauptthemen laut MEDLINE: Mycobacterium Infections, Mycobacterium bovis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCATS NIH HHS, Agence Nationale de la Recherche.
Abstract (Originalsprache)
Purpose
Inborn errors of IFN-γ immunity underlie Mendelian susceptibility to mycobacterial disease (MSMD). Twenty-two genes with products involved in the production of, or response to, IFN-γ and variants of which underlie MSMD have been identified. However, pathogenic variants of IFNG encoding a defective IFN-γ have been described in only two siblings, who both underwent hematopoietic stem cell transplantation (HCST).
Methods
We characterized a new patient with MSMD by genetic, immunological, and clinical means. Therapeutic decisions were taken on the basis of these findings.
Results
The patient was born to consanguineous Turkish parents and developed bacillus Calmette-Guérin (BCG) disease following vaccination at birth. Whole-exome sequencing revealed a homozygous private IFNG variant (c.224 T > C, p.F75S). Upon overexpression in recipient cells or constitutive expression in the patient’s cells, the mutant IFN-γ was produced within the cells but was not correctly folded or secreted. The patient was treated for 6 months with two or three antimycobacterial drugs only and then for 30 months with subcutaneous recombinant IFN-γ1b plus two antimycobacterial drugs. Treatment with IFN-γ1b finally normalized all biological parameters. The patient presented no recurrence of mycobacterial disease or other related infectious diseases. The treatment was well tolerated, without the production of detectable autoantibodies against IFN-γ.
Conclusion
We describe a patient with a new form of autosomal recessive IFN-γ deficiency, with intracellular, but not extracellular IFN-γ. IFN-γ1b treatment appears to have been beneficial in this patient, with no recurrence of mycobacterial infection over a period of more than 30 months. This targeted treatment provides an alternative to HCST in patients with complete IFN-γ deficiency or at least an option to better control mycobacterial infection prior to HCST.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Necker Hospital for Sick Children, INSERM U1163, Paris, France. jeremie.rosain@institutimagine.org.
- University of Paris Cité, Imagine Institute, Paris, France. jeremie.rosain@institutimagine.org.
- Study Center for Primary Immunodeficiencies, Necker Hospital for Sick Children, Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France. jeremie.rosain@institutimagine.org.
- Pediatric Allergy and Immunology, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Necker Hospital for Sick Children, INSERM U1163, Paris, France.
- Pediatric Clinic, IRCCS Policlinico "San Matteo" Foundation, University of Pavia, Pavia, Italy.
ORCID-Profile: Jérémie Rosain, Ayca Kiykim, Alexandre Michev, Yasemin Kendir-Demirkol, Darawan Rinchai, Jessica N Peel, Hailun Li, Tom Le Voyer, Taushif Khan, Anna-Lena Neehus, Mélanie Migaud, Stéphanie Boisson-Dupuis, Nico Marr, Alessandro Borghesi, Jean-Laurent Casanova, Jacinta Bustamante
Förderung
- NIAID NIH HHS
- NCATS NIH HHS
- Agence Nationale de la Recherche
Zitieren
APA
Rosain, J., Kiykim, A., Michev, A., Kendir-Demirkol, Y., Rinchai, D., Peel, J. N., Li, H., Ocak, S., Ozdemir, P. G., Le Voyer, T., Philippot, Q., Khan, T., Neehus, A. L., Migaud, M., Soudée, C., Boisson-Dupuis, S., Marr, N., Borghesi, A., Casanova, J. L., & Bustamante, J. (2024). Recombinant IFN-γ1b Treatment in a Patient with Inherited IFN-γ Deficiency. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-024-01661-5
Vancouver
Rosain J, Kiykim A, Michev A, Kendir-Demirkol Y, Rinchai D, Peel JN, et al. Recombinant IFN-γ1b Treatment in a Patient with Inherited IFN-γ Deficiency. Journal of Clinical Immunology. 2024. doi:10.1007/s10875-024-01661-5
BibTeX
@article{Rosain2024,
author = {Rosain, Jérémie and Kiykim, Ayca and Michev, Alexandre and Kendir-Demirkol, Yasemin and Rinchai, Darawan and Peel, Jessica N and Li, Hailun and Ocak, Suheyla and Ozdemir, Pinar Gokmirza and Le Voyer, Tom and Philippot, Quentin and Khan, Taushif and Neehus, Anna-Lena and Migaud, Mélanie and Soudée, Camille and Boisson-Dupuis, Stéphanie and Marr, Nico and Borghesi, Alessandro and Casanova, Jean-Laurent and Bustamante, Jacinta},
title = {Recombinant IFN-γ1b Treatment in a Patient with Inherited IFN-γ Deficiency},
journal = {Journal of Clinical Immunology},
year = {2024},
doi = {10.1007/s10875-024-01661-5}
}
EUVIMED